GALT Galectin Therapeutics Inc

Price (delayed)

$4.05

Market cap

$408.44M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.43

Enterprise value

$532.87M

?
Relative Growth: Rel. Growth: 7
Relative Strength: Rel. Strength: 73
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 10

Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin’s lead drug belapectin is a carbohydrate-based drug that inhibits ...

Highlights
Galectin Therapeutics's EPS has increased by 33% YoY but it has decreased by 4.9% QoQ
The company's net income rose by 31% YoY but it fell by 6% QoQ
Galectin Therapeutics's quick ratio has shrunk by 95% QoQ and by 93% YoY
GALT's equity is down by 17% year-on-year and by 5% since the previous quarter

Key stats

What are the main financial stats of GALT

GALT stock price

How has the Galectin Therapeutics stock price performed over time
Intraday
-2.17%
1 week
10.05%
1 month
10.05%
1 year
-15.8%
YTD
-2.64%
QTD
-12.72%

Financial performance

How have Galectin Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$15.62M
Net income
-$27.84M
Gross margin
N/A
Net margin
N/A
The operating income has surged by 54% year-on-year and by 4% since the previous quarter
The company's net income rose by 31% YoY but it fell by 6% QoQ

Price vs fundamentals

How does GALT's price correlate with its fundamentals

Growth

What is Galectin Therapeutics's growth rate over time

Valuation

What is Galectin Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Galectin Therapeutics's EPS has increased by 33% YoY but it has decreased by 4.9% QoQ
GALT's equity is down by 17% year-on-year and by 5% since the previous quarter

Efficiency

How efficient is Galectin Therapeutics business performance
GALT's ROIC has shrunk by 65% QoQ but it is up by 32% YoY
The ROA has grown by 21% YoY but it has contracted by 7% from the previous quarter

Dividends

What is GALT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GALT.

Financial health

How did Galectin Therapeutics financials performed over time
Galectin Therapeutics's total assets is 90% less than its total liabilities
Galectin Therapeutics's quick ratio has shrunk by 95% QoQ and by 93% YoY
GALT's current ratio has shrunk by 95% QoQ and by 93% YoY
The debt is 199% more than the equity
GALT's equity is down by 17% year-on-year and by 5% since the previous quarter
The debt has grown by 14% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.